Rocket Pharmaceuticals
RCKT
84 hedge funds and large institutions have $906M invested in Rocket Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 12 closing their positions.
140% more call options, than puts
Call options by funds: $775K | Put options by funds: $323K
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
37% more capital invested
Capital invested by funds: $664M → $906M (+$242M)
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
11% more funds holding
Funds holding: 76 → 84 (+8)
6.64% more ownership
Funds ownership: 86.13% → 92.77% (+6.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$12.2M |
| 3 |
Morgan Stanley
New York
|
+$11.7M |
| 4 |
Goldman Sachs
New York
|
+$11.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$8.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.67M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.66M |
| 3 |
Renaissance Technologies
New York
|
-$4.27M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$2.6M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.48M |
RCKT Hedge Fund Activity: Q3 2018 in Review
84 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2018, worth a combined $906M — up 37% from $664M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RCKT positions and 12 closed out — a net gain of 8 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.3M. The largest seller was Deutsche Bank, cutting an estimated $6.67M.
- 84 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2018, up from 76 in Q2 2018.
- Funds reported $906M of Rocket Pharmaceuticals stock for Q3 2018, up 37% quarter-over-quarter.
- 20 funds opened new Rocket Pharmaceuticals positions in Q3 2018 and 12 closed out, a net change of +8 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2018 was Fidelity Investments, an estimated $23.3M added.
- The largest Rocket Pharmaceuticals seller in Q3 2018 was Deutsche Bank, an estimated $6.67M sold.
Based on aggregated 13F filings for Q3 2018.